IRVINE, CALIF., AND SAN JOSE, CALIF. (PRWEB) NOVEMBER 07, 2022 EmeritusDX and KDx Diagnostics announced today the partnership to provide the URO17 test for the detection of bladder cancer. URO17 is a non-invasive urine test with high sensitivity and negative predicted value (NPV) that can be used to determine the status of active bladder cancer...

SAN JOSE, Calif. and STEVENAGE, England, Dec. 5, 2021 /PRNewswire/ — KDx Diagnostics, Inc. (KDx), and Lister Hospital (East and North Hertfordshire NHS Trust), Stevenage, UK, announced today the launch in the United Kingdom (UK) of KDx’s URO17® test for detection of bladder cancer. This non-invasive urine test for bladder cancer is highly sensitive for identifying...

CAMPBELL, Calif. and CARDIFF, Wales, May 18, 2021 /PRNewswire/ — KDx Diagnostics, Inc. (KDx), Clinical Innovation Accelerator (CIA), Cardiff University, Cardiff and Vale University Health Board C&VUHB) and CellPath, announced today a partnership to develop a non-invasive urine test for suspected bladder cancer patients through the Accelerate programme.  KDx Diagnostics Inc., located in Campbell, CA,...

URO17 is a urine test for detecting bladder cancer in people with symptoms associated with malignancy, including blood in the urine (haematuria) or lower urinary tract symptoms. It is also indicated for detecting urogenital cancer recurrence in the urogenital tract during treatment follow up. URO17 is an immunocytochemistry-based test that detects the presence of the...

KDx Diagnostics, Inc., announced today that it has received Conformité Européene (CE) Marking for its innovative and proprietary urine-based test (the URO17™ test) for bladder cancer … Read More

CAMPBELL, Calif., Jan. 8, 2020 /PRNewswire/ — KDx Diagnostics, Inc. (KDx), announced today that the Food and Drug Administration (FDA) has granted “Breakthrough Device” designation for its URO17™ Bladder Cancer Recurrence Test … Read More

Bladder carcinoma is a common urological cancer with high morbidity, mortality, and recurrence rates requiring frequent, invasive diagnostic procedures Read More 1, Read More 2

A new biomarker allows effective, noninvasive screening of patients at risk of the disease. Bladder cancer presents a diagnostic challenge for even the best pathologists and laboratory medicine professionals Read More

PLAINVIEW, N.Y. and CAMPBELL, Calif., July 25, 2019 /PRNewswire/ — Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, and KDx Diagnostics, Inc., a leading developer of bladder cancer tests, today announced that KDx has licensed Acupath to incorporate its URO17™ … Read More

Cytology and cystoscopy have limited sensitivity and specificity for the diagnosis of urothelial carcinoma ( due to inflammatory atypia, sampling errors, and other clinicopathologic factors that may … Read More